The Summary
This retrospective cohort study tracked 7,938 patients who discontinued semaglutide or tirzepatide after 3 to 12 months of use. Within a year, over 19% restarted their original medication, and 35% tried alternatives like lifestyle counseling, other drugs, or bariatric surgery. On average, patients experienced minimal weight regain one year post-discontinuation (averaging a 0.5% gain for those treating obesity, and a 1.3% loss for those with type 2 diabetes). However, individual weight fluctuations varied widely across the group.
Why this is interesting
Historically, experts feared patients would immediately regain all lost weight after stopping GLP-1s. This real-world study offers a more nuanced picture: while some patients did regain weight, others managed to maintain their progress or even continue losing, often by transitioning to alternative treatments. For readers, this suggests that stopping a GLP-1 doesn't guarantee a return to baseline, but maintaining progress requires a personalized, proactive plan with a healthcare provider to find the right long-term strategy.